Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. · 2010
Read Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. by Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3096954.txt.
Introduction
Prat and colleagues profiled in 2010 a recently recognized breast cancer subtype called claudin-low, filling in its clinical and biological portrait. Breast cancers sort into five gene based subtypes with different outlooks. Claudin-low tumors lack the markers of mature duct lining cells and instead carry signs of a shape shifting program, strong immune gene activity, and stem cell like traits.
Most are triple negative cancers, lacking all three standard drug targets, and they often show unusual growth patterns under the microscope. Their response to chemotherapy before surgery falls between two other subtypes. Widely used lab cell lines and several mouse models turned out to carry this same subtype, a useful accident for research. In a family tree of breast cell maturity, claudin-low sits closest to the mammary stem cell. The paper gives the field a working definition of the subtype.
Catalog record
| CREATOR | Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer By Aleix Prat, Joel S Parker, Olga Karginova, Cheng Fan, Chad Livasy, Jason I Herschkowitz, Xiaping He, Charles M Perou Published in: Breast Cancer Research : BCR DOI: 10.1186/bcr2635 ABSTRACT Introduction In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype. Methods The clinical, pathological and biological features of claudin-low tumors were compared to the other tumor subtypes using an updated human tumor database and multiple independent data sets. These main features of claudin-low tumors were also evaluated in a panel of breast cancer cell lines and genetically engineered mouse models. Results Claudin-low tumors are characterized by the low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-like features. Clinically, the majority of claudin-low tumors are poor prognosis estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation. They also have a response rate to standard preoperative chemotherapy that is intermediate between that of basal-like and luminal tumors. Interestingly, we show that a group of highly utilized breast cancer cell lines, and several genetically engineered mouse models, express the claudin-low phenotype. Finally, we confirm that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell. Conclusions These results should help to improve our understanding of the biologic heterogeneity of breast cancer and provide tools for the further evaluation of the unique biology of claudin-low tumors and cell lines. INTRODUCTION Genomic studies have established four major breast cancer intrinsic subtypes (luminal A, Luminal B, HER2-enriched, basal-like) and a normal breast-like group that show significant differences in incidence, survival and response to therapy [1-3]. However, as gene expression studies evolve, further subclassification of breast tumors into new molecular entities is expected to occur. In 2007, we identified a new molecular subtype, referred to as claudin-low, using 13 samples [5]. These distinct tumors were found in both human and murine breast tumor data sets and were characterized by the low gene expression of tight junction proteins claudin 3, 4 and 7 and E-cadherin, a calcium-dependent cell-cell adhesion glycoprotein. More recently, a tumor initiating cell (TIC) genomic signature derived from CD44+/CD24-/low-sorted cells and mammospheres obtained from primary human breast tumors was found to be exclusively enriched by gene expression in the claudin-low subtype [6,7], and the expression of this CD44+/CD24-/low/claudin-low profile increased in posttreatment samples after neoadjuvant chemotherapy or hormone therapy [7]. Overall, these studies suggest that the claudin-low tumor subtype lacks common epithelial cell features and is enriched for TIC features. In this study, we comprehensively characterize the claudin-low subtype using an updated human tumor database and multiple independent data sets and present the pathological and chemotherapy response characteristics of this subtype of "triple negative" breast cancers. In contrast to the basal-like subtype, we provide evidence that claudin-low tumors are more enriched in epithelial-to-mesenchymal transition (EMT) features, immune system responses, and stem cell-associated biological processes. The molecular characterization of the claudin-low intrinsic subtype in tumors and cell lines reveals a breast cancer differentiation hierarchy that resembles the normal epithelial mammary developmental cascade. MATERIALS AND METHODS Human breast tumor microarray data sets All human tumor and normal tissue samples were collected using Institutional Review Board (IRB)-approved protocols and were obtained from fresh frozen invasive breast carcinomas that were profiled as described previously using oligo microarrays (Agilent Technologies, Santa Clara, CA, USA) [8]; we used all the microarrays from Herschkowitz et al. [5], Parker et al. [9] and Hennessy et al. [6], plus 39 new additional samples presented here. All microarray and patient clinical data are available in the University of North Carolina (UNC) Microarray Database [10] and have been deposited in the Gene Expression Omnibus (GEO) under the accession number GEO:GSE18229 (referred to here as the UNC337 set). The probes or genes for all analyses were filtered by requiring the lowest normalized intensity values in both sample and control to be > 10. The normalized log2 ratios (Cy5 sample/Cy3 control) of probes mapping to the same gene (Entrez ID as defined by the manufacturer) were averaged to generate independent expression estimates. In the resulting UNC337 matrix, no significant batch effects were observed. We also used publicly available microarray and patient clinical data from the following breast cancer data sets: NKI295 [11,12], MDACC133 [13] and NKI113 [14]. In MDACC133, raw data were normalized using the robust multiarray analysis (RMA) normalization approach. In all data sets, genes were median-centered within each data set and samples were standardized to zero mean and unit variance before other analyses were performed. Gene expression signatures We analyzed the mean expression of multiple previously published gene signatures [7,15-19]. Briefly, these signatures include leukocyte-related signatures from Palmer et al. [17]: CD8 (n = 10 genes), B_Cell (n = 286), T_Cell (n = 178), and GRANS (n = 353). Stromal-related signatures were obtained from West et al. [16] (n = 402; DTF and SFT signatures combined) and Beck et al. [19] (n = 174). Genes enriched more than twofold in mammosphere-derived cells compared with differentiated cells were obtained from Dontu et al. [15] (n = 58). From Shipitsin et al. [18], we calculated the mean expression of the upregulated (n = 357) and downregulated (n = 353) genes from CD44+ versus CD24+ breast cancer cells from metastatic pleural effusions. From Creighton et al. [7], we calculated the mean expression of the CD44+/CD24-/low/mammosphere signature reported (n = 119 upregulated genes; n = 279 downregulated genes). Finally, the proliferation and luminal gene cluster signatures were hand-picked (node correlation > 0.75) from the unsupervised intrinsic hierarchical clustering of the UNC337 using the intrinsic list of Parker et al. [9] and average linkage clustering using Cluster v2.12 (M. Eisen) [20] as shown in Figure S1 in Additional file 1. Gene lists from all genomic signatures are displayed in Supplemental Data in Additional file 2. Breast cancer cell line microarray data set We analyzed a data set that included Affymetrix U133A gene expression microarrays of 52 breast cancer cell lines [21]. Raw data were normalized using RMA, and genes were median-centered before analyses. Among the 52 breast cancer cell lines analyzed, DU4475, HCC1008 and HCC1599 cell lines were not included in Neve et al. [21]. Mouse breast tumor microarray data set All mouse samples from the UNC were collected from fresh frozen invasive breast carcinomas as described previously [5] using Agilent mouse oligo microarrays. Data normalization and preprocessing were identical to that described for the UNC337 data set. We used only samples (n = 104) from our previous publication that were included in 1 of the 10 mouse classes [5]. Claudin-low and normal breast Euclidian centroid-based predictors To robustly identify claudin-low samples, we built two predictors on the basis of either our human tumor data or the cell line data of Neve et al. [21]. To build a predictor, we first selected those genes that were significantly